Additionally, sclerostin inhibitors such as romosozumab and setrusumab, representing a novel class of monoclonal antibodies, are currently being investigated in an international clinical trial to evaluate their effectiveness in children with OI [87, 88]. The gene discussed is SOST; the disease is osteogenesis imperfecta.